X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs DISHMAN PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA DISHMAN PHARMA TORRENT PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x 25.0 25.1 99.6% View Chart
P/BV x 6.1 3.3 182.8% View Chart
Dividend Yield % 3.3 0.7 491.5%  

Financials

 TORRENT PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
DISHMAN PHARMA
Mar-16
TORRENT PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720374 459.4%   
Low Rs1,134129 879.4%   
Sales per share (Unadj.) Rs394.5197.8 199.5%  
Earnings per share (Unadj.) Rs101.821.2 480.0%  
Cash flow per share (Unadj.) Rs116.334.7 335.0%  
Dividends per share (Unadj.) Rs40.002.00 2,000.0%  
Dividend yield (eoy) %2.80.8 352.8%  
Book value per share (Unadj.) Rs200.3179.9 111.3%  
Shares outstanding (eoy) m169.2280.69 209.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.61.3 284.2%   
Avg P/E ratio x14.011.9 118.1%  
P/CF ratio (eoy) x12.37.2 169.2%  
Price / Book Value ratio x7.11.4 509.3%  
Dividend payout %39.39.4 416.7%   
Avg Mkt Cap Rs m241,43520,306 1,189.0%   
No. of employees `00010.90.8 1,313.9%   
Total wages/salary Rs m8,5595,355 159.8%   
Avg. sales/employee Rs Th6,129.619,252.7 31.8%   
Avg. wages/employee Rs Th785.86,459.5 12.2%   
Avg. net profit/employee Rs Th1,581.32,064.1 76.6%   
INCOME DATA
Net Sales Rs m66,76415,961 418.3%  
Other income Rs m2,156265 812.5%   
Total revenues Rs m68,92016,226 424.8%   
Gross profit Rs m27,2044,103 663.0%  
Depreciation Rs m2,4611,091 225.6%   
Interest Rs m1,859944 196.8%   
Profit before tax Rs m25,0412,334 1,073.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,414624 1,028.5%   
Profit after tax Rs m17,2241,711 1,006.6%  
Gross profit margin %40.725.7 158.5%  
Effective tax rate %25.626.7 95.8%   
Net profit margin %25.810.7 240.6%  
BALANCE SHEET DATA
Current assets Rs m46,62211,018 423.2%   
Current liabilities Rs m32,8439,517 345.1%   
Net working cap to sales %20.69.4 219.5%  
Current ratio x1.41.2 122.6%  
Inventory Days Days74110 67.2%  
Debtors Days Days7935 226.8%  
Net fixed assets Rs m39,02916,304 239.4%   
Share capital Rs m846161 524.3%   
"Free" reserves Rs m31,40012,907 243.3%   
Net worth Rs m33,89014,516 233.5%   
Long term debt Rs m18,6374,189 444.9%   
Total assets Rs m90,13629,805 302.4%  
Interest coverage x14.53.5 416.9%   
Debt to equity ratio x0.50.3 190.5%  
Sales to assets ratio x0.70.5 138.3%   
Return on assets %21.28.9 237.6%  
Return on equity %50.811.8 431.1%  
Return on capital %48.517.5 276.9%  
Exports to sales %43.324.8 174.8%   
Imports to sales %6.93.7 183.8%   
Exports (fob) Rs m28,9343,956 731.4%   
Imports (cif) Rs m4,584596 768.7%   
Fx inflow Rs m29,1854,952 589.4%   
Fx outflow Rs m6,021697 864.1%   
Net fx Rs m23,1654,255 544.4%   
CASH FLOW
From Operations Rs m27,1322,786 973.7%  
From Investments Rs m-7,014-1,529 458.8%  
From Financial Activity Rs m-14,352-941 1,525.0%  
Net Cashflow Rs m5,767316 1,822.5%  

Share Holding

Indian Promoters % 71.5 61.4 116.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 3.7 189.7%  
FIIs % 12.6 12.7 99.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 22.1 39.8%  
Shareholders   26,511 46,261 57.3%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   NOVARTIS  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Realty Sector Up 2.7%(11:30 am)

After opening the day higher, stock markets in India have continued their momentum. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 23, 2017 11:51 AM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS